Alcon Acquires Neurotech for $550M and Adds ENCELTO Eye Therapy
On October 20, Alcon announced the purchase of privately held Neurotech Pharmaceuticals for $550M. The transaction adds ENCELTO, the FDA-approved cell therapy for adults with MacTel Type 2, to Alcon’s eye-care products. Alcon said the deal should provide a modest lift to 2027 net-sales growth, slightly reduce 2027 core diluted EPS, and contribute positively to EPS afterward.
Why it matters
The acquisition gives Alcon commercial rights to ENCELTO and Neurotech’s cell-therapy platform, expanding its treatment offering for a rare retinal disorder. Alcon expects a small 2027 sales-growth benefit but an initial effect on core diluted EPS, followed by accretion later.
Key facts
- 1Alcon agreed to buy Neurotech Pharmaceuticals for $550M. tradingview.com
- 2ENCELTO received U.S. FDA approval in March 2025 for adults with idiopathic MacTel Type 2. investing.com
- 3Alcon expects the transaction to modestly improve 2027 net-sales growth, slightly weigh on core diluted EPS that year, and become accretive thereafter. stocktitan.net
- 4Approximately 25,000 people in the United States have been diagnosed with MacTel, according to the deal materials. stocktitan.net
Open questions
- One summary describes ENCELTO as expected to receive approval in 2025, while other materials report that FDA approval occurred in March 2025.
- Potential additional payments tied to commercial milestones are mentioned, but their amounts and terms are not disclosed.
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.